Burnout is a well-known phenomenon in healthcare and oncologists have increasingly suffered from burnout, which can lead to mental illnesses and early retirement. Combatting burnout is essential to assure patients continue to receive the care they deserve. During the 2018 annual American Society of Hematology (ASH) meeting, I was interviewed by OBR about research we had done on the topic. This research led to a future publication in the peer-reviewed literature. At the time of this interview, I was a VP and CMO at Cardinal Health Specialty Solutions.

Reimbursement models to practicing physicians continue to evolve. Many oncologists have been skeptical about MACRA (which was enacted into law) and how it might affect their ability to deliver cost-effective care, without compromising patients’ access to life-saving therapies. in this OBR interview, which was conducted during the 2018 annual American Society of Hematology (ASH) meeting, I review findings from market research studies that we conducted when I was at Cardinal Health. This research highlighted the skepticism about MACRA, and should serve as a warning sign to regulators to adjust these models so that patients and physicians are served best. At the time of this interview, I was a VP and CMO at Cardinal Health Specialty Solutions.

During the 2018 annual American Society of Hematology (ASH) meeting and when I was still a VP and Chief Medical Officer at Cardinal Health Specialty Solutions, I gave this interview to OBR on the potential risks faced by oncologists if they enter into a two-sided payment agreement with CMS. Reimbursement models continue to fascinate me and they are rather complex. I am not sure there is a perfect model out there, but let me know your thoughts.

What leads to physicians’ burnout? what are the contributing factors? we delved into this through market research surveys that highlighted the underlying issues. I summarize these in this OBR interview that took place during the 2018 annual American Society of Hematology (ASH) meeting.

As patents for biologics emerge on the marketplace, what will be their role within the cancer community? Will biosimilars provide alternatives for cancer treatment? In addition to alternatives, what information and education is needed for stakeholders to make informed choices about the cancer treatments? During the 2018 annual American Society of Clinical Oncology (ASCO) meeting, I joined Gary Lyman of the Fred Hutchinson Cancer Research in a roundtable discussion hosted by Steve Clemons to discuss the issues. At the time of this live panel that was attended by over 100 ASCO registrants, I was a VP and CMO of Cardinal Health Specialty Solutions. The panel discussion was sponsored by “The Atlantic”. Grounded in the 160-year legacy of the magazine, AtlanticLIVE brings the unparalleled journalism of The Atlantic to life through singular event experiences, on stage and off.